Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach

• Hauptverfasser: Diansong Zhou (Verfasst von), Terry Podoll (Verfasst von), Yan Xu (Verfasst von), Ganesh Moorthy (Verfasst von), Karthick Vishwanathan (Verfasst von), Joseph Ware (Verfasst von), J. Greg Slatter (Verfasst von), Nidal Al‐Huniti (Verfasst von)
• Format: Buch
• Veröffentlicht: Wiley, 2019-07-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Acalabrutinib, a selective, covalent Bruton tyrosine kinase inhibitor, is a CYP3A substrate and weak CYP3A/CYP2C8 inhibitor. A physiologically‐based pharmacokinetic (PBPK) model was developed for acalabrutinib and its active metabolite ACP‐5862 to predict potential drug-drug interactions (DDIs). The...